UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $31. The decision to terminate the lung cancer study with Sasanlimab is attributed to strategic reasons, though high dropout rates raise concerns, particularly regarding the ongoing phase III bladder cancer study.
UBS has maintained a 'Neutral' rating for Pfizer, setting a price target of 31 US dollars. Analyst Trung Huynh noted that the pharmaceutical company's outlook for 2025 did not present any surprises in his initial reaction.
UBS has maintained a 'Neutral' rating for Pfizer, setting a target price of 31 US dollars. Analyst Trung Huynh noted that the pharmaceutical company is starting to regain investor confidence after a mixed performance this year.
UBS has maintained a "Neutral" rating for Pfizer, setting a price target of $31 following a recent conference. Analyst Trung Huynh noted that despite a mixed performance this year, the pharmaceutical company is starting to regain investor confidence.
UBS has maintained a 'Neutral' rating for Pfizer, setting a target price of $31 following an investor event. Analyst Trung Huynh noted the company's presentation on Ponsegromab's potential in treating cancer cachexia, with plans for quarterly updates on its development pipeline.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
